An emerging epidemic of allergic contact dermatitis due to phytonadione epoxide (oxidised vitamin K1).

Autor: Gatica-Ortega ME; Dermatology Department, Complejo Hospitalario Universitario de Toledo, Toledo, Spain.; Escuela Internacional de Doctorado, Universidad de Castilla-La-Mancha, Toledo, Spain., Pastor-Nieto MA; Escuela Internacional de Doctorado, Universidad de Castilla-La-Mancha, Toledo, Spain.; Dermatology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.; Dermatology Department, Hospital Universitario de Guadalajara, Guadalajara, Spain.; Faculty of Medicine and Health Sciences, Medicine and Medical Specialties Department, Universidad de Alcalá, Alcalá de Henares, Spain., Giménez-Arnau AM; Dermatology Department, Hospital del Mar Research Institute, Universitat Pompeu Fabra (UPF) and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain., Mercader-García P; Dermatology Department, Hospital General Universitario Jose Mª Morales Meseguer, Murcia, Spain., Serra-Baldrich E; Dermatology Department, Hospital de La Santa Creu i Sant Pau, Barcelona, Spain., Zaragoza-Ninet V; Dermatology Department, Hospital General Universitario de Valencia, Valencia, Spain., Sanz-Sánchez T; Dermatology Department, Hospital Universitario Infanta Sofia, Madrid, Spain., Sánchez-Gilo A; Dermatology Department, Hospital Universitario Rey Juan Carlos, Madrid, Spain., Pesqué D; Dermatology Department, Hospital del Mar Research Institute, Universitat Pompeu Fabra (UPF) and Universitat Autònoma de Barcelona (UAB), Barcelona, Spain., Tous-Romero F; Dermatology Department, Hospital Universitario 12 de Octubre, Madrid, Spain., Ortiz-de-Frutos FJ; Dermatology Department, Hospital Universitario 12 de Octubre, Madrid, Spain., de la Rosa-Fernández E; Dermatology Department, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain., Dorta-Alom S; Dermatology Department, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain., Elosua-González M; Dermatology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain., González-Pérez R; Dermatology Department, Hospital Universitario De Araba, Vitoria, Spain., Carrascosa-Carrillo JM; Dermatology Department, Hospital Universitari Germans Trias i Pujol, IGTP, UAB, Barcelona, Spain., Munera-Campos M; Dermatology Department, Hospital Universitari Germans Trias i Pujol, IGTP, UAB, Barcelona, Spain., Silvestre-Salvador JF; Dermatology Department, Hospital General Universitario Dr Balmis, ISABIAL, Alicante, Spain., Miquel-Miquel J; Dermatology Department, Hospital Universitario Arnau Vilanova, Valencia, Spain., de Mateo Minguez A; Allergology Department, Hospital Universitario Arnau Vilanova, Valencia, Spain., Borrego L; Dermatology Department, Hospital Universitario Insular de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
Jazyk: angličtina
Zdroj: Contact dermatitis [Contact Dermatitis] 2024 Nov; Vol. 91 (5), pp. 379-386. Date of Electronic Publication: 2024 Aug 20.
DOI: 10.1111/cod.14675
Abstrakt: Background: Reports of allergic contact dermatitis (ACD) to phytonadione epoxide (PE) in cosmetics suggest that PE is as powerful a sensitiser as its parent compound phytonadione.
Objective: To evaluate a case series of ACD to PE in Spain.
Methods: We reviewed the records of 20 patients with ACD to cosmetics containing PE diagnosed across Spain between January 2019 and June 2023.
Results: All 20 patients developed patch test (PT) or repeated open application test (ROAT) reactions to cosmetics containing PE. All involved women with eyelid eczema. PT or ROAT with PE preparations were positive in 17/20 (85%). PE at 1%, 5%, 10% and 20% in pet. was patch-tested in 8/17, 14/17, 11/17 and 8/17 patients; being positive in 6/8 (75%), 13/14 (92.85%), 11/11 (100%) and 8/8 (100%), respectively.
Conclusion: Regulators should, not only ban the specific dangerous cosmetic ingredients, but also consider to ban or keep under close surveillance those closely related products or derivatives that might potentially cause similar harmful effects. PTs with PE are suggested to be performed at a 5% concentration in pet. Higher concentrations (10% pet.) should be tested whenever PTs with 5% pet. PE are negative.
(© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: